Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 34 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

41%

14 trials in Phase 3/4

Results Transparency

13%

3 of 23 completed trials have results

Key Signals

5 recruiting3 with results

Enrollment Performance

Analytics

Phase 1

15(48.4%)

Phase 3

12(38.7%)

Phase 2

2(6.5%)

Phase 4

2(6.5%)

31Total

Phase 1(15)

Phase 3(12)

Phase 2(2)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (34)

Showing 20 of 34 trials

NCT07433556Phase 1Recruiting

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers

Role: lead

NCT04381689Phase 3Active Not Recruiting

Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants

Role: lead

NCT07322991Phase 1Completed

Study to Evaluate the Drug-drug Interaction Between IY001 and IY002 in Healthy Adult Male Subjects.

Role: lead

NCT06284876Phase 3Recruiting

Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer

Role: lead

NCT06461078Phase 1Completed

Clinical Trial to Investigate the Effects of Food on the Pharmacokinetics and Safety of Orally Administered Radotinib

Role: lead

NCT06725992Phase 1Completed

Study to Evaluate Pharmacokinetic and Pharmacodynamic Drug Interactions and Safety of IY-NS250 and IY-NT-SR

Role: lead

NCT06665412Recruiting

Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML

Role: lead

NCT03459534Phase 3Recruiting

A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

Role: lead

NCT03722420Phase 3Active Not Recruiting

Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)

Role: lead

NCT04691661Phase 2Recruiting

Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease

Role: lead

NCT06471868Phase 1Active Not Recruiting

Study to Evaluate Pharmacokinetic and Pharmacodynamic Drug Interactions and Safety of IY-HCR21 and IY-MIC

Role: lead

NCT05509543Phase 1Completed

Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T

Role: lead

NCT06181591Phase 2Not Yet Recruiting

A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)

Role: collaborator

NCT02677493Phase 3Completed

Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'

Role: lead

NCT05558150Phase 1Completed

Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Ilaprazole and Aceclofenac

Role: lead

NCT05237297Phase 1Completed

Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Naproxen, Aceclofenac, Celecoxib and Ilaprazole

Role: lead

NCT05617651Phase 1Unknown

Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T

Role: lead

NCT03444883Phase 3Completed

Phase III Study to Evaluate Safety and Efficacy of Ilaprazole in Patients With NERD

Role: lead

NCT02480998Phase 1Completed

Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean Adults

Role: lead

NCT02638584Phase 4Completed

Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.

Role: lead